3B Blackbio DX Ltd (3BBLACKBIO) is currently trading at 1,329.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

3B BlackBio DX Limited is an Indian biotech and diagnostics company focused on molecular diagnostics (TRUPCR PCR kits, enzymes and reagents), Next‑Gen Sequencing assays (TRUNGS), and rapid tests (TRURAPID), while retaining legacy agrochemical operations; the company recently acquired Coris BioConcept (Belgium) and operates manufacturing and R&D facilities recognized by DSIR and ISO standards. Management reported consolidated nine‑months revenue of INR99.06 crore (including Coris) versus INR64.80 crore earlier, with 3B standalone growing around 11.8% year‑on‑year and management guiding consolidated revenue growth of 10%–15% for the full year, while exports are expected to outpace domestic growth at 15%–20% given strengthened European and other geographies. The Coris acquisition materially changes revenue composition and capabilities: Coris contributed approximately INR24 crore in the quarter, including a ~INR8.8 crore one‑off from a HAT government supply contract, and management is pursuing US FDA clearance and selective IVDR certifications to convert regulatory investment into market access for Europe and the US. Competition intensity is rising as adjacent diagnostic players enter molecular diagnostics attracted by higher margins, but 3B emphasizes SKU breadth, technical support, and workflow efficiency to retain stickiness; management is balancing organic R&D (multiplex panels, dPCR, sample‑to‑answer) with inorganic growth via acquisitions to protect and expand market share. The company holds cash and acquisition firepower (management cited roughly INR190 crore cash position with INR130–140 crore available for acquisitions while retaining reserves), intends to prioritize profitable scale and M&A integration, and flags short‑term EBITDA pressure from merger‑related one‑offs while targeting improved profitability at Coris next year.

Over the past 52 weeks, 3B Blackbio DX Ltd has traded between a low of ₹1,083.50 and a high of ₹1,750.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

3B Blackbio DX Ltd has a market capitalization of approximately 1,138.88. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

3B Blackbio DX Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.24 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,138.88 Cr, 3B Blackbio DX Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

3B Blackbio DX Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of 3B Blackbio DX Ltd is 20.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting to consider and approve the unaudited Q1 FY27 standalone and consolidated results is scheduled for August 13, 2026, at 3:00 P.M., per the BSE filing.

FY26 consolidated revenue from operations was ₹141.92 crore and consolidated PAT was ₹59.93 crore, versus ₹96.47 crore and ₹47.69 crore in FY25.